Posted by Michael Wonder on 11 Mar 2016
FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer
11 March 2016 - The U.S. FDA today approved Xalkori (crizotinib) to treat people with advanced (metastatic) non-small cell lung cancer whose tumors have an ROS-1 gene alteration.
For more details, go to: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm490329.htm
